
# **EMR Tutorial Acute Coronary Syndrome**

# How to find the Acute Coronary Syndrome

## AAA Home

Southin MEDICAL 45	AST TOTAL	Pat	Test Jr (409)555-5555 ient's Code Stat	us Full Code		<u>) View Alerts</u>
		Initiative I Pro harge Posting Tuto Nursing Home I	-	de Tutorial E8M (	Hypertension I M Coding Recommendations hysical Therapy Podiatry	ledical Home Coordination Needs Attention!! Rheumatology
	Exercise	Hydration I M I Asthma Cl Weight	I <u>Diabetic E:</u> Iutrition I <u>G</u> Diseas IF I <u>Diabete:</u> Management	xercise I Drug.In uidelines I Labf se Management s I Headaches I	teractions I <u>Smoking Cesse</u> Future I Lab Results I	lanagement I tion I ardiometabolic Risk Syndrome I
Patient's CVS - J	Pharmacy	Pending Ref	Priority	Referral	Referring Provider	Chart Note
	(409)384-3582	Completed	Routine	Thyroid Biopsy	Holly	Return Info
hone		Completed	Stat	Sleep Studies	Wilson	Return Doc
ax	(409)383-0816	Completed	Immediate	СТ	Holly	Ernail
Ro	K Sheet - Active	Completed	Immediate	Carotid Doppler	Holly	Telephone
R	tx Sheet - New					Records Request
Rx	Sheet - Complete				•	Transfer of Care Doc
	Home Health	Internet	ferrals - Do no	ot use for new ref	Potorrol History	
		Status	Priority	Referral	Referring Provider	

Master Tool Bar Icon



- When the Template button is clicked you will be presented with the preference list.
- If the Acute Coronary Syndrome template is listed as one of your preferences, select it.
- If it is not one of your preferences, select the All radio button and scroll down until you find it in the list. Then you may select the template by either double-clicking on the name or single click on the name (so that it is highlighted in blue) and then click the OK button.

NOTE: For more on how to set up your preferences, Click Here

One of the most difficult and one of the most important differential diagnoses which confront physicians in the outpatient setting is the distinguishing between chronic stable angina and the acute coronary syndrome. The former is a relatively benign condition which can be safely and successfully treated in the outpatient setting. The latter is a potentially fatal condition which requires immediate intervention to decrease the mortality risk of the patient.

This suite of templates in conjunction with the Angina Suite of Templates has been developed in order to aid the healthcare provider in making that distinction accurately and quickly.

The Acute Coronary Syndrome Suite of Templates consists of the following templates:

- Master Acute Coronary Syndrome
- Q-Wave
- Evaluation
- Differential Dx
- NESTMI/Unstable Angina Treatment
- Q-Wave MI Treatment

Acute	Coro	nary Syndrome	Patient Greg	Те	st Jr	
		as "rule out MI," but think "rule me" (MI and Unstable Angina).	Sex M	Age Check		Home
	<u>Goals</u>	Definition	HGB		11	Q-Wave
Vital Signs		Risk Factors	HCT		11	Evaluation
Temp 63.0		✓ Diabetes ✓ Dyslipidemia ✓ Family Hx of Premature CAD	WBC hsCRP Homocysteine			Differential Dx Treatment
Veight 100	0.01 lb	(under 55 for males, 65 females)	Sed Rate	<u> </u>	11	NESTMI/Unstable Angina
BMI Body Fat 30	_ %	History of CVA	Cholesterol HDL	3000 140	04/08/2009	Q-Wave MI
Pulse Blood Pressure		History of MI	Chol/HDL		11	Document
	mmHg	<ul> <li>Hypertension</li> <li>Overweight/Obese</li> <li>Sedentary lifestyle</li> <li>Smoking</li> </ul>	Triglycerides Trig/HDL Fasting Glucose Insulin	5000	04/08/2009	
Framingham 10-Yr Framingham 10-Yr Hubbard Probability TIMI Risk Score Global Cardiovaso	Stroke Ris / Severe C		HOMA-IR Ca Mg Ca/Mg UA Protein MS Strip Creat/Albumin CPK Troponin		1 / / 1 / / 1 // 3/2009 7 / / 7 / 7 / 7 / 7 /	

The Master Acute Coronary Syndrome Template Content:

The following statement begins the suite, "Do not think of chest pain as 'rule out MI,' but think 'rule out acute coronary syndrome' (MI and Unstable Angina)."

The first button is entitled **Goals**. It contains six goals of the evaluation of the patient for ACS. They are:


	Acute Cord	onary Syndrome	Patient Greg		Test Jr	
		n as "rule out MI," but think "rule rome" (MI and Unstable Angina).		M	Age Check for New Labs	Home
	Goals	Definition	HGB		11	Q-Wave
Vital Sigr	าร	Risk Factors	HCT	ł	11	Evaluation
Temp	F	Diabetes	WBC hsCRP	ł		Differential Dx
Height	n Acs Goals	IV Dyslipidemia	nscrup	,	×	Treatment
vve						NESTMI/Unstable Angina
BMI Boc		Goal	S			Q-Wave MI
Pul: Blo	<ul> <li>To assist practitioners in distinguishing among patients with acute coronary syndromes (AMI, unstable</li> </ul>					
		ioners in accurately stratifying patients v risk of morbidity or mortality	with possible acute c	oronar	y syndrome into high,	
	<ul> <li>To minimize the unstable angina</li> </ul>	number of patients discharged from the	ED with unrecognize	d myoc	cardial infarction or	
<u>Fra</u> <u>Fra</u> Hut	will result in ear	e hospitalization rates for patients having rlier diagnosis and decreased hospital le led critical care areas and improve over	ngth of stay. These t	wo fea		
<u>TIM</u> Glo	10.000000000000000000000000000000000000	ent satisfaction by providing earlier and uses for their chest pain symptoms	more definitive diagn	osis of	either cardiac or	
		sician satisfaction by providing a strate discharge from the ED without over utili				
		ОК	Cancel			
L						]

The second button	is entitled	Definition.	It states:
-------------------	-------------	-------------	------------


Ac	ute Coronary Syndrome	Patient Greg	Τε	est Jr		
	k of chest pain as "rule out MI," but think "rule	Sex M	Ag	e		
out acute co	oronary syndrome" (MI and Unstable Angina).	Latest Lab Results	Check	for New Labs		Home
	Goals Definition	HGB		11		Q-Wave
Vital Signs	Risk Factors	HCT		11		Evaluation
Temp	F Diabetes	WBC		11		Differential Dx
Height	63.00 in 🔽 Dyslipidemia	hsCRP	<u> </u>	11	Troa	tment
Weight	100.0 lb	Homocysteine	<u> </u>			TMI/Unstable Angina
BMI	(under 55 for males, 65 females)	Sed Rate Cholesterol	3000	04/08/2009	NES	
Body Fat	30 % History of PVD	HDL	140	04/08/2009		Q-Wave MI
Pulse	m Acs Definition	TIDE		0110012000	×	Document
Framingh Eramingh Hubbard TIMI Risk Global Ca	Acute coronary syndrome (ACS) refers to the acut includes a spectrum of illness ranging from the first myocardial infarction (Q-wave and non-elevated S' with unstable angina, but exicudes patients with ch	onset of angina up to a wave MI (NESTMI)).	and inclu	uding acute		
		Creat/Albumin	_			

In the first column of the **Master Acute Coronary Syndrome** template, the following then appears:


- Vital signs
- Framingham 10-yr CVD Risk
- Framingham 10-Yr Stroke Risk
- Hubbard Probability Severe Coronary Disease
- TIMI Risk Score
- <u>Global Cardiovascular Risk</u>




In the second column, 10 Risk Factors are listed which increase the probability that the patient could be having the ACS.



In the third column, 22 lab tests are displayed which are relevant to the evaluation of the patient potentially with the ACS. There is a button entitled **Check For New Labs** which allows you to import the latest lab values for the evaluation.




In the fourth column are the navigation buttons followed by the button entitled **Document**, which when depressed creates a document for this suite of templates.



#### **Q-Wave Template**


The full name of this template is "**Comparison of Q wave and non-Q wave MI**." Nine characteristics of a Q-Wave MI and 10 Characteristics of a Non-Q Wave MI are displayed.



# Comparison of Q Wave and Non-Q Wave MI

Q-Wave	Non Q-Wave	Return
Presents with ST-segment elevation	Presents with ST-segment depression	
High in-hospital mortality	Lower in-hospital mortality	
Lower reinfarction rate after hospital discharge	High reinfarction rate after hospital discharge	
Thrombolysis beneficial	Thrombolysis not recommended	
Sustained coronary artery occlusion	Early spontaneous reperfusion common	
Large infarct size	Small infarct size	
Acute complications common	Acute complications uncommon	
1-mo mortality rate, 10%-15%	1-mo mortality rate, 3%-5%	
2-yr mortality rate, 30%	2-yr mortality rate, 30%	

#### **Evaluation Template**



The full name of this template is, "Key Diagnostic Items to be Elicited for Assessing Significant CAD in Patients with Chest Pain Suggestive of Acute Coronary Syndrome."

	ostic Items to be Elicited for Assessi with Chest Pain Suggestive of Acute		Return
Time of Onset of Pain	Critical for determining whether the patient should receive thrombolytic agents if an AMI is present . Sensitivity and specificity of cardiac markers are time dependent.	Onset Date //	
Duration and Persistence of Pain	Helpful in the classification of chest pain. Features suggestive of noncardiac chest pain include constant pain lasting days or fleeting pain lasting a few seconds or less.	Duration/Persistence	Deutiel
Character of Pain	Pain which is pleuritic, reproduced by movement or palpation of the chest or arms, or localized with one finger is suggestive of noncardiac chest pain but does not completely exclude the diagnosis of ischemic pain.	Type of Chest Pain Class of Angina	Partial Sample
Associated Symptoms	Helpful in assigning a cardiac diagnosis (as they are anginal equivalents), they include	<ul> <li>+</li> <li>Shortness of breath</li> <li>Nausea</li> <li>Diaphoresis</li> <li>Light headedness</li> </ul>	
History of AMI or Invasive Procedures	Prior AMI as determined by history or ECG findings of Q waves or a history of invasive procedures for CAD such as CABG or PTCA are the most important indicators of severe CAD.	Cardiac History	
Age and Gender	Older age and male gender have been consistently shown to be predictive of MI or USA in the ED setting. The management of patients over age 65 continues to be more complex and demanding than of younger patients. It has also been shown that women with chest pain are less aggressively evaluated.	Sex M	
		and the second se	

There are ten parts to this template. They are explained below:

The first two are:

• **Time of Onset of Pain** – there is a place to document the date and time of onset of the pain.

Time of Onset of Pain	Critical for determining whether the patient should receive thrombolytic agents if an AMI is present .	Onset Date //
	Sensitivity and specificity of cardiac markers are time dependent.	Time

• **Duration and persistence of Pain** – there is a place to document how long the pain has lasted.

Duration and	Helpful in the classification of chest pain.	Duration/Persistence
Persistence of Pain	Features suggestive of noncardiac chest pain include constant pain lasting days or fleeting pain lasting a few seconds or less.	

The next two are:

• Character of Pain – there are two buttons here which link you to the Angina Suite of templates for Type of Chest Pain and Class of Angina. For more information on Angina, <u>Click Here</u>.

Character of Pain	Pain which is pleuritic, reproduced by movement or palpation of the chest or arms, or localized with one finger	Type of Chest Pain
	is suggestive of noncardiac chest pain but does not completely exclude the diagnosis of ischemic pain.	Class of Angina

• Associated Symptoms.—four angina equivalents are displayed so that you can note them if they are present.

Associated Symptoms	Helpful in assigning a cardiac diagnosis (as they are anginal equivalents), they include	<ul> <li>Shortness of breath</li> <li>Nausea</li> <li>Diaphoresis</li> <li>Light headedness</li> </ul>
------------------------	---	--

#### The next two are:

#### **History of AMI or Invasive Procedures** – there is a link here to the **Cardiac History Age and Gender** – these two elements are displayed automatically

History of AMI or Invasive Procedures	Prior AMI as determined by history or ECG findings of Q waves or a history of invasive procedures for CAD such as CABG or PTCA are the most important indicators of severe CAD.	Cardiac History
Age and Gender	Older age and male gender have been consistently shown to be predictive of MI or USA in the ED setting.	Sex M
	The management of patients over age 65 continues to be more complex and demanding than of younger patients. It has also been shown that women with chest pain are less aggressively evaluated.	Age

Associated Risk Factors – there is a place to document the presence of the five major risk factors for coronary artery disease

Associated Risk Factors	Diabetes is the most important risk factor, but cigarette smoking, hypercholesterolemia, and hypertension are also important predictors of significant CAD.	<ul> <li>Diabetes</li> <li>Dyslipidemia</li> <li>Hypertension</li> <li>Sedentary lifestyle</li> <li>Smoking</li> </ul>

**Drug Use** – if patient's use or non-use of elicit drugs is automatically noted from the History template. A link to the List of **Elicit Drugs** in the patient's **History** is present here

			-	
Drug Use	Cocaine and amphetamine abuse can cause bot unstable angina .	h Mi and	listory of drug use	
	Cocaine can also cause an elevation of serum C that are unrelated to AMI.	K enzymes	f Elicit Drugs	
Add Social Hx				×
	Habit Det	ail		
	igarettes" box if the patient CURRENTLY smo ed smoking ONLY after you have entered the			n suk
Tobacco PPD	# Years Date Stopped	🗖 Drugs	# Years Date Stopped	
<ul> <li>✓ Cigarettes</li> <li>2</li> <li>Cigars</li> <li>Pipes</li> <li>Smokeless</li> </ul>	20     Stopped?     / /       20     Stopped?     / /       Stopped?     / /       Stopped?     / /       Stopped?     / /	Cocaine	10 / / / / / / / / / / /	
Alchohol Beer Wine Mixed	oz/wk         Date Stopped           80.00         / /           .00         / /           .00         / /	Toxic Substanc	:es	
Caffeine 10	Cups / Cans per day			
		Exercise		
Comment	8	Training		
	ок	Cancel		

# **Physical Examination** – this lists the **Physical Findings suggestive of CAD** and **Signs/cause of secondary unstable angina**.

Physical Exam	Physical findings suggestive of CAD include	<ul> <li>S3 or S4 sound or gallop</li> <li>Mitral regurgitant murmur</li> <li>Paradoxically split S2</li> <li>Bibasilar rales</li> <li>Chest wall heave that disappears when pain subsides</li> <li>Peracardial rub</li> </ul>
	Signs/causes of secondary unstable angina include	<ul> <li>Pallor or tachycardia from anemia</li> <li>Pulse abnormalities</li> <li>Atrial fibrilation</li> <li>Bradycardias</li> </ul>
		<ul> <li>Proptosis</li> <li>Thyromegaly</li> <li>Hyperactive reflexes</li> <li>Tachycardia</li> <li>Skin changes to suggest hyperthyroidism</li> </ul>

Next there is:

## ECG – there is a link to the ECG Report from the Procedures template in NextGen.


ECG	High likelihood of CAD if: ST increase or decrease >=1 mm; Marked symmetrical T wave inversions in multiple precordial leads; dynamic changes with chest pain Intermediate likelihood of CAD if: ST depression .5 to 1 mm; T wave inversion >=1 mm in leads with dominant R waves	EKG Report
	Low likelihood of CAD: A normal ECG; T wave flat or inverted < 1 mm in leads with dominant R waves	

## **Differential Diagnosis Template**

This is a pop-up which displays other potential causes of the pain which is commonly associated with the **Acute Coronary Syndrome**.

<b>Il Signs</b> Temp	ary syndrome" (MI and Unstable a Goals Definition Risk Factors F V Diabetes 3.00 in V Dyslipidemia	HGB HCT WBC hSCRP	Check for New Labs		Home Q-Wave Evaluation Differential Dx Treatment
		to Acute Coronary S Pulmonary Disease Pulmonary embolism Pneumonia Pieuritis Pneumothorax Psychogenic hyperventilati Chest Wall Pain Musculoskeletal Neurologic	Syndrome	×	NESTMI/Unstable Angina Q-Wave MI Document
	Pancreatitis	Cancel			

#### **NESTIMI and Unstable Angina Treatment**



This template begins with the statement, "Once unstable angina or non-SET Segment has been identified, standard anti-ischemic treatments should be initiated."


The template then displays 15 standard anti-ischemic treatments which can be initiated. Two of these Calcium Channel Blockers and Thrombolytic Therapy are not generally used with unstable angina and/or non-ST-segment elevation MI. All of the treatments which are in blue have links to documents which give more information about each of these treatments.

Treatment for NSTEMI	and Unstable Angina	
Once unstable angina or non-ST-segment elevation MI has bee should be initiated.	n indentified, standard <b>anti-ischernic</b> treatments	Return
Bed rest     Continuous ECG monitoring for possible arrhythmias <u>Oxygen</u>	Anticoagulant Therapy	AHA Antiplatelet Recommendations AHA Anticoaqulant Recommendations Glycoprotein Trials
Nitrates     Morphine     Beta-blockers <u>Calcium channel blockers</u> (generally not used)	Low-molecular-weight heparins     Thrombolytic therapy (generally not used)     Statin therapy	
Long-acting dihydropidine calcium channel blockers Angiotensin-converting enzyme inhibitors	Antiplatelet therapy	

Under the navigation button to the right there are three information documents:

- AHA Antiplatelet Recommendations
- AHA Anticoagulant Recommendations
- Glycoprotein Trials


#### **Q-Wave MI Treatment Template**



At the top of this template is the statement, "Glycoprotein IIb/IIIa therapy is recommended in moderate to high-risk patients."

The instruction is then given, "Select one of the following options...

• Is Cath lab treatment planned within 12 hours?



• Is the patient to receive medical management ONLY or is cath lab treatment postponed for more than 123 hours?

Treatment for Q-Wa∨e MI	
Glycoprotein IIb/IIIa therapy is recommended in moderate to high-risk patients.	
Select one of the following options Clear	Return
Is cath lab treatment planned within 12 hours?	
Is the patient to receive medical management ONLY or is cath lab treatment postponed for more than 12 hours?	
* IV heparin (5000 U bolus, then 800-1000 U/hr to maintain APTT between 50-60 secs)*	
* IV tirofiban (Aggrastat®) for up to 108 hours (0.4 ug/kg/min) for 30 minutes, then 0.1 ug/kg/min)	
* Beta blocker (to keep heart rate < 60 bpm); i.e., metroprolol 50mg bid	
* Aspirin 325 mg qd (chewable)	
* Nitrate therapy (IV, long acting oral, or topical)	
* Note: Enoxaparin 1mg/kg s.o. bid may be considered instead of unfractionated IV/heparin; however, the combination of an LMWH and a GP IIb/IIIa inhibitor has not been well studied.	
* Note: If PCI is performed, continue Rx with IV Aggrastat for 12 hours after procedure.	

# At the bottom of this template, there are five links:

Monitoring and Assessment Medications Complications in Q-Wave MI Treatment Recommendations EKG Changes

# • Monitoring and Assessment

Treatment for Q-Wa∨e MI
Glycoprotein IIb/IIIa therapy is recommended in moderate to high-risk patients.
Select one of the following options Clear
C is cath lab treatment planned within 12 hours?
O Is the patient to receive medical management ONLY or is cath lab treatment postponed for more than 12 hours?
Monitoring and Assessment         Medications         Complications in Q-Wave MI         Treatment Recommendations         EKG Changes           Dm Acs Ownimoni         X
Monitoring and Assessment
Since administration of llb/lla antagonists may be associated with an increased frequency of thrombocytopenia and major bleeding complications, the following precautions should be taken:
1. Obtain CBC with platelets at baseline, 6 and 24 hours following administration, then qd.
2. Obtain troponin level at baseline and 8 hours after admission
<ol> <li>Discontinue drug if platelets decrease to less than 100,000 or by 25% of pre-treatment value (assess peripheral smear to r/o pseudothrombocytopenia)</li> </ol>
4. Assess for signs of bleeding:
Observe for mental status changes
Observe eyes for hemorrhage Assess mucous membranes of nose and mouth
Monitor puncture and access sites
Examine urine, stool, and emesis for signs of frank blood Guaiac stool and Hemastix for presence
5. If significant bleeding occurs:
Discontinue GP llb/lla and heparin therapy
Consider infusion of 12 units platelets (or PRBC/FFP) if clinically indicated Stat CBC and platelets
Fem-stop or direct pressure for groin bleed.
OK Cancel

• **Medications** – this is an electronic PDR for 9 categories of medications which are used in the treatment of Acute Coronary Syndrome.

Select one of the following option C Is cath lab treatment planned		moderate to high-risk patients.		Return	
Dm Acs Drugs	te Ropt Antagonists ors ibitors			<u>; Changes</u>	×
3. Review the available info General Dosir		Interactions	Pregnancy	Precautions	
** Pediatri	c Dose Not Established	Cancel			

# • Complications in Q-Wave IM

	tment for Q-Wa∨e MI apy is recommended in moderate to high-risk patients.	
	Apy is recommended in model die to night tak patients.	Return
Select one of the following options Clear Select one of the following options Clear Is cath lab treatment planned within 12 hours	.7	
	··· ONLY or is cath lab treatment postponed for more than 12 hours?	
Monitoring and Assessment Medications	Complications in Q-Wave MI Treatment Recommendations EKC	Changes
Monitoring and Assessment Medications	Complications in g-wave init	o changes
Dm Acs Qwavecomp		×
Complication	s in Q-Wa∨e Myocardial Infarction	
Complication	s in Q-wave wyocardiar infarction	
Complication	Management	
🗁 Bradyarrhythmias	Atropine, pacemakers	
Congestive heart failure	Vasodilators, IV inotropic agents, diuretics (use with caution), IABP	
	(intra-aortic balloon pumping)	
Hypotension	Volume replacement, inotropic agents, vasodilators, IABP, mechanica revascularization	Ě.
	TOYGOUGHZARDT	
Papillary muscle rupture	Inotropic agents, vasodilators, IABP, mechanical revascularization	
Pericarditis	Nonsteroidal anti-inflammatory drugs	
🗖 Recurrent ischemia	Nitrates, beta-blockers, morphine, repeated reperfusion	
C Ventricular fibrillation	Defibrillation, amiodarone, beta-blockers	
Ventricular septal rupture	Inotropic agents, vasodilators, IABP, mechanical revascularization	
🦳 Ventricular tachycardia	Lidocaine (Xylocaine) HCl, amiodarone HCl (Cordarone, Pacerone), beta-blockers, synchronized defibrillator-cardioverter shock	
	OK	

### • Treatment Recommendations

	ent for Q-Wave MI recommended in moderate to high-risk patients.
O is the patient to receive medical management ONLY	for is cath lab treatment postponed for more than 12 hours?
nitoring and Assessment Medications Com	plications in Q-Wave MI Treatment Recommendations EKG Changes
Dm Acs Treatrec	×
Therapy for	Acute Coronary Syndrome
Treatment	Recommendations
Adenosine Diphosphate Receptor Inhibitor	Consideration of clopidogrel (Plavix) therapy in selected cases
Antiplatelet Agent	Aspirin, 325 mg (chewable)
Beta-Blocker	IV therapy optional for prompt response, followed by oral therapy:
	* Metoprolol (Lopressor), 5 mg IV every 5 min for three doses
	* Propranolol HCI (Inderal), 1 mg IV; may repeat every 5 min for total of 5 mg
	* Esmolol HCI (Brevibloc), initial IV dose of 50 micrograms/kg/min and adjust up to 200-300 micrograms/kg/min
Cardiac Catheterization	Consideration of early invasive approach in patients at intermediate to high risk and those in whom conservative management fails
Enoxaparin Sodium (Lovenox)	1 mg/kg IV, followed by 1 mg/kg subcutaneously bid
Glycoprotein IIb/IIIa Receptor Inhibitors	Abciximab (ReoPro), eptifibatide (Integrilin), or tirofiban HCl (Aggrastat) for patients with high-risk features in whom an early invasive approach is planned
T Heparin	Goal: aPTT (activated partial thromboplastin time), 1.5-2.5 X control
T Nitrates	Sublingual nitroglycerin (NitroQuick, Nitrostat), one tablet every 5 min for total of three tablets initially, followed by IV form (Nitro-Bid IV, Tridil) if needed
	OK Cancel

# • EKG Changes

Treatment for Q-Wave MI         Glycoprotein IIb/IIa therapy is recommended in moderate to high-risk patients.         Select one of the following options Clear         Image:	Return
Monitoring and Assessment Medications Complications in Q-Wave MI Treatment Recommendations <b>EKG C</b>	hanges X
EKG Changes in Q-Wa∨e MI	
<ul> <li>The electrocardiogram (ECG) remains a key tool in the diagnosis of Q wave infarction; serial tracings provide critical diagnostic inference of Q wave infarction is acute ST-segment elevation in association with severe chest pain.</li> <li>Significant ST-segment elevation is defined as 0.10 mV or more measured 0.02 second after the J point in two contiguous leads, from the following combinations: <ol> <li>I leads II, III, or aVF (inferior infarction),</li> <li>I leads V1 through V6 (anterior or anterolateral infarction), or</li> <li>I leads I and aVL (lateral infarction).</li> </ol> </li> <li>Abnormal Q waves usually develop within 8 to 12 up to 24 to 48 hours after the onset of symptoms.</li> <li>Abnormal Q waves are at least 30 msec wide and 0.20 mV deep in at least two leads from the combinations listed.</li> <li>Complete left bundle branch block: <ol> <li>In the appropriate clinical setting (acute, severe chest pain suggestive of myocardial ischemia) should be managed as ac myocardial infarction pending cardiac marker analysis.</li> <li>It is usually not possible to definitively diagnose acute myocardial infarction by the ECG alone in the setting of left bundle to the diagnosis of either posterior or right ventricular myocardial infarction requires specific analysis worthy of detailed recombinations is of the posterior or right ventricular myocardial infarction requires specific analysis worthy of detailed recombinations is of either posterior or right ventricular myocardial infarction requires specific analysis worthy of detailed recombinations is of either posterior or right ventricular myocardial infarction requires specific analysis worthy of detailed recombinations is of either posterior or right ventricular myocardial infarction requires specific analysis worthy of detailed recombinations is of either posterior or right ventricular myocardial infarction requires specific analysis worthy of detailed recombinations is a second proving and proving proving proving proving proving proving proving p</li></ol></li></ul>	ute oranch block.

**Document** – this generates the summary of the use of this suite of templates.

